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Abstract
Aim: The aim of this study was to compare the extent of cognitive impairment and the types of cognitive
deficits in an Australian cohort of four patient groups with end stage kidney disease. Characteristics predicting
the presence of cognitive impairment were also evaluated.
Methods: Observational cross sectional study of one hundred and fifty five patients with end stage kidney
disease recruited from a regional Australian renal unit. Eligible participants included those whose estimated
Glomerular Filtration Rate was < 30 ml/min per 1.73m2; were undertaking peritoneal or hemodialysis, or had
received a kidney transplant. The Montreal Cognitive Assessment tool was used to screen the study
participants for cognitive impairment and evaluate cognitive deficits. Cognitive impairment was defined as a
total Montreal Cognitive Assessment tool score ≤24/30.
Results: The extent of cognitive impairment varied between the four groups with end stage kidney disease.
Factors predicting the presence of cognitive impairment included undertaking dialysis, age ≥65, male gender,
and the presence of diabetes or cerebrovascular disease. Deficits in executive function, attention, language,
visuospatial skills, memory and orientation were common amongst the study participants, and these deficits
varied according to which end stage kidney disease group the participants were in. Limitations to the study
included the cross sectional design and that the presence of confounders like depression were not recorded.
Conclusion: The impact of disparities in the cognitive capabilities identified in this study are likely to be far
reaching. Tailoring of education and self management programs to the cognitive deficits of individuals is
required.
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Title: A comparison of the extent and pattern of cognitive impairment among predialysis, 
dialysis and transplant patients: a cross sectional study from Australia 
Aim: The aim of this study was to compare the extent of cogntive impairment and the types 
of cognitive deficits in an Australian cohort of four patient groups with end stage kidney 
disease. Characteristics predicting the presence of cognitive impairment were also evaluated. 
Methods: Observational cross sectional study of one hundred and fifty five patients with end 
stage kidney disease recruited from a regional Australian renal unit. Eligible participants 
included those whose estimated Glomerular Filtration Rate was < 30ml/min/1.73m
2
; were 
undertaking peritoneal or hemodialysis, or had received a kidney transplant. The Montreal 
Cognitive Assessment tool was used to screen the study participants for cognitive impairment 
and evaluate cognitive deficits. Cognitive impairment was defined as a total Montreal 
Cognitive Assessment tool  score ≤24/30.  
Results: The extent of cognitive impairment varied between the four groups with end stage 
kidney disease . Factors predicting the presence of cognitive impairment  included 
undertaking dialysis, age ≥65, male gender, and the presence of diabetes or cerebrovascular 
disease. Deficits in executive function, attention, language, visuospatial skills, memory and 
orientation were common amongst the study participants, and these deficits varied according 
to which end stage kidney disease group the participants were in.  Limitations to the study 
included the cross sectional design and that the presence of confounders like depression were 
not recorded.  
Conclusion: The impact of disparities in the cognitive capabilities identified in this study are 
likely to be far reaching. Tailoring of education and self management programs to the 
cognitive deficits of individuals is required.    
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Introduction  
Self management of End Stage Kidney Disease (ESKD) requires patients to evaluate and 
respond to changes in clinical symptoms (such as blood glucose levels); to manage and 
adhere to multifaceted medication regimens (such as phosphate binders), and to implement a 
complex and often contradictory dietary prescription. Unfortunately, self management can be 
compromised by cognitive impairment (CI) (1, 2). 
 
The evidence suggests that CI is common in people undertaking dialysis (especially 
hemodialysis), and that dialysis patients differ significantly from normal controls with respect 
to the prevalence of CI (3-6). For example, it has been estimated that 8.6-19% of the general 
population have CI (7-11), whereas 28.9% (12) to 80% (13-15) of dialysis patients may have 
CI. However, the literature is unclear regarding the extent of CI in those with ESKD not 
undertaking dialysis, and the evidence regarding transplant patients is conflicting  (16, 17). 
 
While evidence is consistent that cognitive deficits in orientation, attention and executive 
function are common in hemodialysis patients (3);  the evidence is much less clear about the 
cognitive deficits in other groups with ESKD (3, 18) .  This is an important knowledge gap 
because CI is well recognised as an independent predictor of mortality in people with ESKD 
(19, 20), and because it can adversely impact on decision making ability and judgement (21). 
Correctly identifying those with CI, and understanding the types of cognitive deficits has 
significant implications for the design and delivery of health information (such as dietary 
education materials), and self management programs for people with ESKD.   
 
The Montreal Cognitive Assessment Tool (MoCA) has been recommended as an ideal 
screening tool for CI in people with ESKD (13). This is due to the higher sensitivity and 
specificity of the MoCA when compared to the Mini Mental State Exam (22). The MoCA 
assesses a number of cognitive capabilities including executive function, visuospatial skills, 
attention, language, memory and orientation (23). However, no studies have compared the 
differences in CI or the types of deficits that may exist between the four common groupings 
of patients with ESKD: those considered predialysis; and those undertaking a renal 
replacement therapy such as hemodialysis, peritoneal dialysis or a kidney transplant. 
Similarly, there have not been any studies published utilising this tool in people with ESKD 
in the Australian setting 
 
Therefore, the aims of this study were to explore whether CI was present among four 
common groups of patients with ESKD, and to compare and contrast the nature of any 
cognitive deficits exhibited by these different groups. In addition, factors potentially 
predictive of CI, such as age, gender and comorbid disease were also explored.  
 
Subjects and Methods  
Invitations to participate in this cross sectional study were sent by mail to all adult patients 
(≥18 years of age) with ESKD (n=227) attending the renal unit of a large regional Australian 
hospital. This included patients with ESKD not undertaking dialysis (ie those with an 
estimated GFR<30ml/min/ 1.73m
2
) (PRE group); those undertaking peritoneal dialysis (PD 
group) or hemodialysis (in centre or at home) (HD group); and those who had received a 
kidney transplant (KT group). Patients with dementia or known CI, as determined by their 
treating renal physician, were excluded from the study, as were patients with an acute illness 
in hospital.  
 
The MoCA tool (23) was administered by one of three research dietitians  after receiving 
written informed consent from the participant. Training regarding the administration and 
scoring of the MoCA was conducted according to the instructions provided by the author of 
the MoCA and freely available on the website www.mocatest.org. For those with poor vision, 
the ‘blind’ version of the MoCA (24) was used. For those undertaking  hemodialysis in 
centre, the MoCA was administered during the second hour of the patient’s hemodialysis 
session within the renal unit. This was intentional and was designed to assess cognitive 
capabilities at a time when health professionals often provide education to patients receiving 
hemodialysis. Professional interpreter services were used with the relevant translated version 
of the MoCA to complete the assessment with patients who could not communicate in 
English.  Scores on the MoCA range from 0 to 30 with a  higher score being indicative of 
better cognition. A cut off value of ≤ 24/30 was used to indicate the presence of CI (13). 
Calculation of the scores for the domains of executive function, visuospatial skills, attention, 
language, working memory and orientation utilised the method dsecribed by the authors of 
the MoCA (23).   
  
Demographic and clinical information such as age, gender, educational level, comorbid 
chronic disease burden, dialysis adequacy and duration of renal replacement therapy were 
obtained from the patient records. Details regarding the presence of  chronic disease were 
limited to the presence of lung disease, coronary artery disease, peripheral vascular disease, 
diabetes, cerebrovascular disease and cancer. These chronic diseases were chosen because 
this information is routinely collected for all patients receiving a renal replacement therapy in 
Australia (i.e. dialysis or a transplant) (25). The definition of comorbidity used in this study 
was three chronic conditions, because this is considered the norm for people with chronic 
kidney disease (26). Approval for the study was received from the local human research 
 
ethics committee [removed for blinded peer review] and all participants provided written and 
verbal consent.  
 
Statistical analysis was performed using SPSS (version 21; SPSS, Chicago, IL, USA). The 
Shapiro-Wilk Test was used to assess normality. Scores for the MoCA and its subcomponent 
scores was negatively skewed and were therefore transformed via reflection and log10 prior 
to analysis. Differences between groups were analysed using the independent samples t-test 
or one-way analysis of variance with post hoc analysis using the Bonferroni post hoc test for 
multiple comparisons. Data is reported as mean and 95% confidence interval, and proportions 
scoring below normative values for normal controls.  Categorical variables are expressed as 
counts and percentages (%) and were evaluated using Pearson’s Chi Square test.  Spearman’s 
correlation coefficient (rho) was used to determine the relationship between age, dialysis 
adequacy and duration of renal replacement therapy (RRT) with total MoCA score and sub 
scores. Logistic regression was used to determine predictors of CI. The dependent variable of 
CI was dichotomised using a cut off score of ≤ 24/30 (13). All independent variables with a 
p<0.10 in univariate analyses or variables known to be associated with CI in the four groups 
with ESKD (eg PVD (19)) were included in the final model. Statistical significance was set at 
a p value of 0.05.  
 
Results  
A total of 155 individuals agreed to participate in the study (giving an overall response rate of 
68.3%). Study participants did not differ from those who declined to participate for age, 
gender or English speaking status. However, there were significantly more predialysis 
patients in the group who declined to participate (p<0.001). The median age of the 
participants was 66 years (Interquartile range, IQR: 55-75), with  patients in the transplant 
 
group being  significantly younger (58.5 (IQR: 49-66) years) than the other three groups 
(p<0.001, Table 1). The majority of study participants were males (n= 92, 59.4%), had less 
than 12 years of schooling (n=88, 56.8 %) and were undertaking  either hemodialysis (n=54, 
35%) or had received a transplant (n= 52, 34%) (Table 1).  The transplant group had a 
signficantly longer duration of renal repalcement therapy compared to the dialysis groups 
(median duration 8.1 years (IQR: 4.1-14.3), p<0.001). Both the peritoneal and hemodialysis 
groups were achieving dialysis adequacy  as evidenced by their Kt/v values (27, 28). The 
mean estimated GFR of the predialysis group was 11.9ml/min (sd 4.7) indicating stage 5 
chronic kidney disease. 
 
Information regarding comorbid disease burden was not available for 25% (n=41) of the 
participants including all of the predialysis patients. Half of the participants had more than 
three comorbidities (Table 2), with almost three quarters of the hemodialysis group (n=32, 
71.1%) having more than 3 comorbidities. Moreover, the hemodialysis group had 
significantly greater proportions of patients with coronary artery disease and peripheral 
vascular disease than the kidney transplant group. Furthermore, more than one third (n=17, 
34.7%) of the kidney transplant group had cancer, and this was signficantly higher than all 
other groups.  
 
Binary logistic regression was undertaken to identify independent predictors of the presence 
of CI. Independent predictors were found to be: undertaking dialysis (OR 3.09, 95% 
confidence interval: 1.07-8.94, p=0.04); age ≥ 65 (Odds Ratio [OR] 3.31, 95% confidence 
interval: 1.14-9.65, p=0.03); male gender (OR 3.09, 95% confidence interval: 1.07-8.89, 
p=0.04); and the presence of cerebrovascular disease (OR 4.98, 95% confidence interval: 
 
1.27-19.45, p=0.02) or diabetes (OR 3.76, 95% confidence interval: 1.10-12.93, p=0.04)  
(Table 3).  
 
As dialysis was found to be an independent predictor of the presence of CI, the total MoCA 
scores of the dialysis and non-dialysed patients (predialysis and transplant) were compared 
(Table 4a). Results indicate that dialysis patients had signficantly lower total MoCA scores 
(p<0.001) and CI was more commonly present in this patient group than the non-dialysed 
group (53.2% vs 18.4%, p<0.001). Further analysis of the differences between the four 
groups indicate that CI  was present in all four groups with ESKD (Table 4b). However, 
disparities were apparent in the extent and severity of CI between these groups.The 
proportion of participants with a MOCA score ≤ 24 (indicating CI was present) did not differ 
between the peritoneal and hemodialysis groups (48.0% versus 55.6%, respectively).  The 
hemodialysis group (55.6%) however, had a significantly higher proportion of patients with 
CI, compared to the predialysis (16.7%)  and kidney transplant groups (19.2%). These results 
are further reflected in the total MoCA scores (Table 4b) highlighting that the hemodialysis 
group had significantly lower mean MoCA scores than the predialysis and kidney transplant 
groups.  
 
Analysis of the correlation between age, RRT duration and dialysis adequacy with total 
MoCA scores and scores for the individual domains within the MoCA are summarised in 
Table 5. There was a statistically significant negative association between increasing age and 
total MoCA score, which was also the case for  the following MoCA domains; executive 
function, visuospatial skills, memory and language (Table 5). In additon, RRT duration was 
weakly associated with attention scores (Spearman’s rho =-0.20; p=0.01). Dialysis adequacy 
(as assessed by Kt/V) was not associated with any domain or total MoCA score in either the 
 
hemodialysis or peritoneal dialysis groups. . Further analysis of the relationship between 
eGFR in the predialysis group and total MoCA score was undertaken. This indicated there 
was a non-significant relationship between the two variables of eGFR and total MoCA score 
(n=24; Spearman’s rho 0.06, p=0.80). 
 
An examination of the extent and types of cognitive deficits present in the four groups with 
ESKD is shown in Figure 1. This figure illustrates the proportion of participants achieving 
MoCA scores below normative values (norms) for normal controls (29). The norms were 
derived from 90 healthy older community dwelling Canadians with a normal 
neuropsychological profile and mean age of 72.8 years (23). In this study, deficits in 
executive function were present in all four groups. More than half of the dialysis patients 
scored below norms compared to 29.2% of the predialysis and 38.5% of the kidney transplant 
groups.  Deficits in visuospatial skills were apparent in half of the predialysis and 44.4% of 
the hemodialysis groups and this was significantly greater than in the transplant group 
(15.4%, p<0.05).  Deficits in attention were apparent in more than one quarter of the dialysis 
and transplant groups. Language skills were impaired in all four groups, and to the greatest 
extent in the peritoneal (60%) and hemodialysis (57.4%) groups. The cognitive domain that 
was most impaired in all four groups was memory, which affected at least 50% of 
participants in each of the four groups. Eighty five percent of the hemodialysis group 
exhibited impairment in this cognitive domain, and this was significantly higher than the 
predialysis (54.2%) and transplant groups (51.9%, p<0.05). Deficits in orientation were 
uncommon in most groups,  except the hemodialysis group where 46.3% of the hemodialysis 





In this cross sectional observational study of four groups of Australian patients with ESKD, 
we have shown that CI was present in all four groups with ESKD, although disparities were 
apparent in the types and extent of cognitive deficits. Identified predictors of CI included 
undertaking dialysis, age ≥ 65, male gender, and the presence of diabetes or cerebrovascular 
disease. These predictors were common among the study participants indicating that the 
findings of this study have important implications for the design and delivery of health 
information and self management programs for people with ESKD.   
 
Our results regarding the extent of CI are similar to previous studies showing that CI is more 
common in those undertaking hemodialysis (13, 19, 30-33); in those who are older (12, 14, 
19, 34); and that CI was equally common in adequately dialysed peritoneal and 
haemodialysis patient groups (35). However, our results regarding the extent of CI in those 
undertaking peritoneal dialysis is higher than almost all previous studies published (12, 14, 
36-38). We speculate that the variations from previous studies on the prevalence of CI in 
peritoneal dialysis are the result of using different assessment tools or applying different 
study methods when using the MoCA. For example, previous work by Shea et al (12) using 
the MoCA to screen for CI in those receiving peritoneal dialysis in Hong Kong, utilised a cut 
off of 21 or 22/ 30 based on previous validation studies in their setting, compared to a cut off 
≤ 24/30 in this study. 
 
There is scarce literature available describing and comparing the cognitive capabilites of 
predialysis and transplant groups. Our finding, that CI was present in around one in every six 
predialysis patients (16.7%), and one in every five kidney transplant patients (19.2%),  
suggests that the prevalence of CI in these groups are not different to that in the general 
 
population (7-11) or previous research in these groups (39-41). However, it remains 
important to note that a substantial number of predialysis and kidney transplant patients still 
demonstrated impairments (ie scores below normative values (23)) in the cognitive domains 
of executive function, visuospatial skills, language and memory, which may in part be  
related to comorbid disease burden. Further research with larger sample sizes is required in 
these patient groups to evaluate this hypothesis, as well as to examine the potential impact of 
impairments in these domains on self management of ESKD. 
 
Successful self management requires a range of skills. These skills include: problem solving; 
making decisions; finding and using relevant resources; developing a partnership between the 
patient and health professional; making, taking and sustaining self management actions; and 
applying and tailoring information obtained to suit the needs of the individual (42). However, 
all of these components of self management require adequate cognition to be successful (43). 
In the heart failure context for example, it has been shown that self management programs 
conducted without consideration given to the self management capacity and cognitive 
capabilities of particpants are likely to be ineffective (44, 45). It is therefore surprising, that 
there is very little research that directly addresses, or even acknowledges, the potential impact 
of CI on self management in ESKD. Future efforts should therefore be directed to exploring 
this aspect in more detail in patients with ESKD.  
 
The most common CI related deficit in this study for each of the four patient groups was 
memory, and similar to the findings of O’Lone et al (3), where no difference was seen in the 
extent of memory deficits between the peritoneal and hemodialysis groups. These findings 
are important because deficits in memory can directly impact on our patient’s ability to learn 
and recall information provided, subsequently affecting their self-management skills of 
 
problem solving, decision making, finding appropriate resources, and sustaining self-
management actions. It is also worth noting that MoCA specifically tests working (or short 
term) memory; and some have suggested that individuals with diminished working memory 
are probably incapable of adhering to treatment recommendations (even if motivated) due to 
an inability to retain and retrieve new information (46). Further research into the use of 
memory aids or cognitive stimulation training (47) and how these impact on self management 
in ESKD is required.  
 
Deficits in executive function were apparent in all four groups of ESKD participants included 
in the current study. This is a key finding because diminished executive function could 
impact on the ability of an individual to successfully self monitor, and to make and sustain 
appropriate behaviour change in relation to their self management goals (42). Research on the 
impact of deficits in executive function in ESKD are lacking. However, research in other 
chronic disease cohorts has demonstrated that deficits in executive function are strongly 
asssociated with medication non adherence in older adults (48); poor self management in 
individuals with diabetes (49) and higher mortality rates in individuals with heart failure (50).  
Strategies often used to improve adherence, such as motivational interviewing or health 
coaching are likely to be ineffective in individuals with diminished executive function, 
because normal cognitive function and ability to control impulsive behaviour is assumed.  
 
Finally, deficits in language and attention, like those reported in this study, would also be 
expected to compromise the ability to learn and perform self management successfully. 
Diminished language skills are believed to be a good indicator of the likelihood that an 
individual is not able to adequately comprehend and follow advice (46).  In this study, 
impairments in language were experienced by more than 25% of participants in all four 
 
groups.  Poor scores on MoCA items relating to language are believed to represent poor 
retention of auditory information, and in the self management context, may lead to 
mishearing instructions or hearing only part of the message (51). Individuals with diminished 
language skills may also have difficulties reading, writing and recalling self-management 
tasks and goals; as well as undertaking multistep instructions for the same reason. Adequate 
skills in attention are also an important component of learning how to self manage.  Some 
authors have stated that attention is considered to be the foundation of learning (52). Deficits 
in attention therefore reduce the ability of the individual to selectively focus on a given task 
long enough to accomplish a goal. This skill was especially problematic for those in the 
hemodialysis group, and in around one in every three patients in the peritoneal dialysis and 
kidney transplant groups. Studies investigating the utility of specific strategies to improve 
language and attention deficits in individuals with ESKD are warranted. 
 
The clinical implications of our findings are that self management support and patient 
education, that are specifically tailored to the cognitive capabilites, coexisting comorbid 
disease burden and health literacy skills (53) of the patient with ESKD, are necessary. We 
believe that the results of our study also support the proposition that health professionals 
should routinely screen all people with ESKD for CI,which would help to identify patients at 
risk of poor treatment adherence.  In this study, older males undertaking dialysis, with 
diabetes and cerebrovascular disese would be a high risk group for CI and we suggest they 
would be likely to struggle with self management of their ESKD. Further research is required 
into the timing and feasibility of innovative tailored approaches to patient education and self 
management in people with ESKD. This is an integral part of providing high quality 
personalised, patient centred health care (54, 55). This is especially important in nephrology 
 
where patients are complex and exhibit multimorbidity, frailty, CI and other geriatric 
syndromes (17). 
 
There are several important limitations to this research. Firstly, the cross sectional nature of 
this study with relatively small patient numbers prevents inferences regarding the potential 
changes in cognition that may occur when changing between modailities. Unequal numbers 
between patient groups may have also impacted on our findings. Longitudinal studies with 
larger sample sizes investigating how cognitive capabilities change over time were not 
possible in this study but are currently underway by other research groups (56, 57). Secondly, 
confounders such as the presence of depression was not recorded in this study, and yet it is 
well known that depression is strongly associated with CI (37). Similarly, the comorbid 
disease status was not recored for approximately 25% of participants  in this study (including 
all predialysis patients). The fact that those with known cognitive impairment were excluded 
from the study may understimate the prevalence of CI.  The lack of normative values for 
patients with kidney diease may also be a potential limitation.The normative values used in 
this study have also been used in several previous studies with younger CKD populations and 
found that the MoCA still showed high sensitivity and specificity in these CKD populations 
(13, 58). Further, the MoCA has been shown to be age and gender independent (59). We 
therefore believe that the use of these norms and the results obtained in this study are 
appropriate. Additional limitations may include failing to account for several other potential 
confounders such as cardiovascular disease, stroke, anemia and uremic toxins. Further 
investigation of these potential confounders on cognitive impairment is required. Future work 
exploring the unexplained, but statistically significant negative relationship between attention 
and RRT duration is also warranted. The strengths of this study include the nature of the 
study design and high participant response rate. Finally, even though the results of this study 
 
are from a single centre in one local health district,  our participants were similar to 
ANZDATA Registry 2014 (25) figures for age, gender and number of comorbidities. We also 
believe this to be the first study that has described the extent of CI and the types of cognitive 
deficits in those with ESKD in an  Australian setting.  
 
In summary, the extent of CI and deficits in executive function, attention, language, 
visuospatial skills, memory and orientation varied between the four ESKD groups 
investigated as part of this study. Predictors of CI included older age (≥65 years),  male 
gender, undertaking dialysis and diagnosed with diabetes and/or cerebrovascular disease. 
These findings provide valuable information which can be used to tailor education and self-
management interventions to better suit the needs of these different patient groups.   
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Figure 1. Proportion of study participants (n=155) with MoCA domain scores below 
normative values for normal controls  
 
PRE: Predialysis group; PD: Peritoneal Dialysis group; HD: Hemodialysis group:  KT: 
Kidney Transplant recipient group 
Values with this superscript (#) are significantly different from all other groups (p<0.001) and 





































































Male, n (%) 
 
11 (45.8) 13 (52.0) 36 (66.7) 32 (61.5) 92 (59.4) 0.30 
<12 years of education, n (%) 13 (54.2) 18 (72.0) 54 (63.0) 23 (44.2) 88 (56.8) 0.09 
 













Dialysis adequacy (Kt/v) 
median (IQR) 




N/A N/A N/A 
Estimated Glomerular Filtration Rate 
(ml/min), mean (SD) 
11.9 (4.7) N/A N/A 58.3 (18.3) 43.1 (26.7) N/A 
 
PRE: Predialysis group; PD: Peritoneal Dialysis group; HD: Hemodialysis group:  KT: Kidney Transplant recipient group 
IQR: Interquartile range; N/A: not applicable 
# Values with this superscript are significantly different from all other groups.  
a: Peritoneal dialysis adequacy indicated by Kt/V>1.7 (Reference: 27) 




















Lung disease, n (%) 
 
N/A 3 (15.0) 12 (26.7) 8 (16.3) 23 (20.2) 0.38 
Coronary Artery Disease, n (%) 
 
N/A 8 (40.0) 27 (60) 
a
 13 (26.5) 
a
 48 (42.1) 0.004* 
Peripheral Vascular Disease, n (%) 
 
N/A 4 (20.0) 26 (57.8) 
a
 16 (32.7) 
a
 46 (40.4) 0.01* 
Diabetes, n  (%) 
 
N/A 7 (35.0) 23 (51.1) 14 (28.6) 44 (38.6) 0.08 
Cerebrovascular Disease, n (%) 
 
N/A 2 (10.0) 14 (31.1) 8 (16.3) 24 (21.1) 0.09 
Cancer, n  (%) 
 
N/A 1 (5.0) 9 (20.0) 17 (34.7) 
#
 27 (23.7) 0.02* 
More than 3 comorbidities, n (%) 
 
N/A 9 (45.0) 32 (71.1) 
a
 16 (32.6) 
a
 57 (50.0) <0.0001* 
 
PRE: Predialysis group; PD: Peritoneal Dialysis group; HD: Haemodialysis group:  KT: Kidney Transplant recipient group; N/A: not available 
# Values with this superscript are significantly different from all other groups.  
a: values with this superscript are significantly different from each other.  




Table 3.Logistic regression analyses of factors associated with the presence of cognitive 
impairment 
 
Factor Odds Ratio 95% CI P value 
Dialysis 3.09 1.07-8.94 0.04* 
Age ≥ 65 3.31 1.14-9.65 0.03* 
Male gender 3.09 1.07-8.89 0.04* 
Cerebrovascular disease 4.98 1.27-19.45 0.02* 
Diabetes 3.76 1.10-9.65 0.04* 
≥ 3 comorbidities 0.28 0.03-2.48 0.26 
< 12 years of education 1.57 0.60-4.13 0.36 
Peripheral Vascular Disease 0.36 0.09-1.49 0.16 
Coronary Artery Disease 2.73 0.54-13.79 0.22 
 
*indicates statistically significant (p<0.05) 
 
Table 4a.MoCA results of study participants according to those undertaking dialysis vs no dialysis.  
 Dialysis 
(PD and HD group) 
n=79 
 
Non dialysis  
(PRE and KT group) 
n=76 
D vs ND 
P value 
Cognitively impaired,  
Proportion, n, (%) 
42 (53.2) 14 (18.4) <0.001* 
Total MoCA score  




























Cognitively impaired,  
Proportion, n, (%) 
4 (16.7) 
a






 56 (36.1) <0.001* 
Total MoCA score  



















PRE: Predialysis group; PD: Peritoneal Dialysis group; HD: Hemodialysis group:  KT: Kidney Transplant recipient group 
*P value <0.05 denotes statistical significance 
a,b: values with this superscript are significantly different from each other.  
 
Table 5. Analysis of the correlation between age, RRT duration and dialysis adequacy with 









Dialysis adequacy  
(n=69) 
 
Spearman’s rho  
(p value) 












Total MoCA score  
 




-0.25 (0.002) * 0.07 (0.41) 0.07 (0.64) -0.13 (0.63) 
Visuospatial score 
 
-0.18 (0.03) * 0.05 (0.52) 0.23 (0.11) -0.06 (0.82) 
Memory score 
 
-0.32 (<0.001) * 0.04 (0.66) 0.07 (0.62) 0.02 (0.93) 
Attention score 
 
-0.08 (0.34) -0.20 (0.01) * -0.05 (0.72) -0.38 (0.13) 
Language score 
 
-0.24 (0.003) * -0.06 (0.44) 0.006 (0.97) -0.23 (0.38) 
Orientation score 
 
-0.12 (0.13) -0.04 (0.96) 0.007 (0.96) N/A 
 
Indicates statistically significant (p <0.05). HD: Hemodialysis; PD: Peritoneal Dialysis. 
Dialysis adequacy assessed using Kt/V and represents 96% of all HD patients, 68% of all PD 
patients, and overall 87% of all dialysis patients in the study N/A: not applicable as all 
participants scored maximum points and unable to calculate correlation 
 
